Compare · NVO vs WHWK
NVO vs WHWK
Side-by-side comparison of Novo Nordisk A/S (NVO) and Whitehawk Therapeutics Inc. (WHWK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and WHWK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 1002.1x WHWK ($173.3M).
- Over the past year, NVO is down 28.6% and WHWK is up 30.2% - WHWK leads by 58.7 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 2 for WHWK).
- NVO has more recent analyst coverage (25 ratings vs 4 for WHWK).
- Company
- Novo Nordisk A/S
- Whitehawk Therapeutics Inc.
- Price
- $38.82-1.05%
- $2.87-5.12%
- Market cap
- $173.66B
- $173.3M
- 1M return
- -10.14%
- -29.83%
- 1Y return
- -28.57%
- +30.16%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 4
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest WHWK
- Stifel initiated coverage on Whitehawk Therapeutics with a new price target
- Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
- Amendment: SEC Form 4 filed by CHIEF FINANCIAL OFFICER Giacobello Scott M.
- Amendment: SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Lennon David James
- Amendment: SEC Form 4 filed by Officer Ball Bryan
- Amendment: SEC Form 4 filed by Chief Scientific Officer Dornan David
- Amendment: SEC Form 4 filed by Chief Medical Officer Dugan Margaret
- SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Lennon David James
- SEC Form 4 filed by CHIEF FINANCIAL OFFICER Giacobello Scott M.
- SEC Form 4 filed by Chief Medical Officer Dugan Margaret